This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for Jan 13, 2022
by Zacks Equity Research
U.S. stocks closed slightly higher on Wednesday after data showed that inflation hit a four-decade high but came in largely in line with economists' expectations.
IMV Doses First Patient in the Mid-Stage Study With Keytruda
by Zacks Equity Research
IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $81.20, moving -0.58% from the previous trading session.
Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug
by Zacks Equity Research
Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.
Gilead (GILD) Partners With Merck for Keytruda in NSCLC Study
by Zacks Equity Research
Gilead (GILD) and Merck collaborate to evaluate the former's breast cancer drug in combination with the latter's blockbuster drug Keytruda for NSCLC study.
Merck (MRK) Keytruda Betters Survival in Adjuvant Lung Cancer
by Zacks Equity Research
Merck's (MRK) phase III study evaluating Keytruda for adjuvant stage IB-IIIA non-small cell lung cancer (NSCLC) meets one of its dual primary endpoints of disease-free survival (DFS).
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.
Absci (ABSI) Inks Research Agreement With Merck, Stock Up
by Zacks Equity Research
Absci (ABSI) signs a deal with Merck for using its AI-powered drug creation platform to produce enzymes for Merck's biomanufacturing applications with an option for the development of three novel drugs.
Exelixis (EXEL) Amends Agreement With Iconic Therapeutics
by Zacks Equity Research
Exelixis (EXEL) gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic.
Merck (MRK) Stock Moves -0.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $78.83, marking a -0.06% move from the previous day.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
5 Small-Cap ETFs to Profit From the January Effect
by Sweta Killa
After registering double-digit annual growth, Wall Street is poised to gain from the historical trend of January Effect.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?
by Zacks Equity Research
Sector ETF report for RYH
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag
by Zacks Equity Research
The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.
Here's Why Pfizer (PFE) Appears Strongly Placed for 2022
by Kinjel Shah
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RYH
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $77.14, marking a +0.25% move from the previous day.
Can-Fite (CANF) Files Patent Applications for Namodenoson
by Zacks Equity Research
Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.
5 Sector ETFs That Crushed the Market in December
by Sweta Killa
With just a few trading sessions left to end December, the S&P 500 index has gained 4.8%. A few sector ETFs have outperformed.
Can Veklury Sales Retain Momemtum for Gilead (GILD) in 2022?
by Zacks Equity Research
Solid sales from Veklury cushion Gilead (GILD) in 2021 amid COVID-19. However, new oral antivirals in the market might hurt sales. GILD now shifts focus to oncology as the virology space faces issues.
Stock Market News for Dec 27, 2021
by Zacks Equity Research
U.S. stocks closed higher for the third consecutive day on Thursday, with the S&P 500 hitting a record high ahead of a long Christmas holiday weekend as investors shed fears and felt more optimistic that the Omicron variant of the coronavirus won¿¿¿t affect global economy growth.
The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Adobe, Merck, Edwards Lifesciences and Norfolk Southern Corp
Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use
by Zacks Equity Research
Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.